PepGen Appoints Dr. Steve Han as Senior VP to Advance Oligonucleotide Therapies
- PepGen appoints Dr. Steve Han as Senior VP of Clinical Development to enhance its focus on innovative therapies.
- Dr. Han's expertise will advance PepGen's pipeline for treating severe neuromuscular and neurological diseases.
- PepGen grants Dr. Han stock options, emphasizing commitment to attracting top talent for clinical development initiatives.
PepGen Strengthens Leadership with Appointment of Dr. Steve Han
PepGen Inc., a clinical-stage biotechnology firm specializing in advanced oligonucleotide therapies, enhances its leadership team with the recent appointment of Dr. Steve Han as Senior Vice President of Clinical Development. This strategic move is aimed at bolstering the company’s focus on developing innovative treatments for severe neuromuscular and neurological diseases. Dr. Han brings significant expertise to PepGen, which has invested over a decade in research to refine its Enhanced Delivery Oligonucleotide (EDO) platform. This platform utilizes cell-penetrating peptides to improve the delivery and efficacy of oligonucleotide therapeutics, addressing the underlying causes of serious health conditions.
To incentivize his employment, PepGen grants Dr. Han a non-qualified stock option package allowing him to purchase 95,000 shares at an exercise price of $4.40 per share. This stock option is structured to vest over four years, with 25% becoming available on the one-year anniversary of his employment and the rest vesting monthly thereafter, contingent upon his ongoing service with the company. This inducement grant was approved through PepGen’s 2024 Inducement Plan, which aligns with Nasdaq Listing Rule 5635(c)(4) and underscores the company’s commitment to attracting top-tier talent to lead its clinical development initiatives.
Dr. Han's appointment is a pivotal development for PepGen as the company seeks to advance its robust pipeline of therapeutic candidates. By focusing on innovative oligonucleotide therapies, PepGen aims to make significant strides in treating critical health challenges faced by patients with severe diseases. The leadership change comes at a crucial time for the company, as it positions itself to leverage Dr. Han's expertise to enhance its clinical strategies and expedite the development of its promising therapeutic candidates.
In addition to Dr. Han's appointment, PepGen remains active in expanding its research initiatives and reinforcing its commitment to addressing serious medical conditions through innovative solutions. The company’s dedication to its EDO platform not only highlights its potential in the biotechnology space but also reflects the ongoing evolution of treatment approaches for debilitating diseases. PepGen's strategic decisions, including leadership appointments and research advancements, signal its ambition to become a leader in the biotechnology industry. For more information, interested parties can visit PepGen's official website or follow them on social media platforms.